Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors. Convert’s proprietary insights in both the tumor microenvironment and specific biomarkers as well as the chemical design of prodrugs guide the development of these next-generation therapeutics.

Latest news

Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, announces that Dr Mariola Söhngen joined as CEO, as the company gears up for its first-in-human clinical trials with its lead program....

Convert Pharmaceuticals has been granted a total of EUR 13,6 million in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive support by the Walloon region and the European Eurostars program. The funds will be used to prepare and conduct initial clinical studies with Convert’s lead anti-cancer drug, which may bring a novel approach to tackling certain aggressive and resistant tumors....